Need professional-grade analysis? Visit stockanalysis.com
$13.89B
N/A
354
N/A
Shanghai Bao Pharmaceuticals Co., Ltd. (2659) trades on Hong Kong Stock Exchange in HKD. The company is classified in the Healthcare sector under the Biotechnology industry. The stock currently trades at HKD89.65, up 1.88% from the previous close.
Over the past year, 2659 has traded between a low of HKD88.00 and a high of HKD115.00. The stock has lost 16.7% over this period. It is currently 22.0% below its 52-week high.
Shanghai Bao Pharmaceuticals Co., Ltd. has a market capitalization of $13.89B.
Shanghai Bao Pharmaceuticals Co., Ltd. operates as a clinical-stage biotechnology company. The company uses synthetic biology technology to develop and deliver recombinant biologic drugs in Mainland China, Hong Kong, Macau, and Taiwan. Its products include KJ017, a recombinant human hyaluronidase; KJ103, an recombinant immunoglobulin G (IgG)-degrading enzyme; SJ02, a long-acting recombinant human follicle-stimulating hormone carboxyl-terminal peptide fusion protein (FSH-CTP); BJ044, a recombinant ulinastatin developed through synthetic biology; BJ007, a SC administered ceftriaxone sodium for the treatment of bacterial infections; and KJ101, a recombinant human chymotrypsin developed through synthetic biology. The company also develops drug design platform, chassis cell engineering platform, and comprehensive bioprocessing platform. The company sells its products under the Bao Pharma brand name. Shanghai Bao Pharmaceuticals Co., Ltd. was founded in 2019 and is based in Shanghai, China.
Side-by-side comparison against top Healthcare peers.